Ads
related to: Stelara- See Treatment Results
Help Relieve Your PsA Symptoms
With A Once-Daily Pill.
- Watch Video
Watch A Video To Learn More
About A Treatment For PsA.
- PsA Treatment Options
Treatment Didn't Work?
See Additional Treatment Options.
- FDA-Approved PsA Pill
Not Meeting Your Treatment Goals?
Try Our Pill With Proven Results.
- Try A Different Treatment
Still Experiencing PsA Symptoms?
A Change In Treatment Can Help.
- Find A Rheumatologist
Find A Rheumatologist Near You.
Set Goals For PsA Treatment.
- See Treatment Results
Search results
Stelara biosimilar from Alvotech, Teva approved by FDA
BioPharma Dive via Yahoo Finance· 2 days agoThe FDA cleared Selarsdi for treatment of moderate to severe plaque psoriasis and active psoriatic...
J&J first-quarter revenue misses as Stelara sales disappoint By Reuters
Investing.com· 3 days agoStelara sales were flat at $2.45 billion in the first quarter and came in below expectations of $2.6...
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks via Yahoo Finance· 8 hours agoJ&J Begins Q1 Earnings Season: J&J’s first-quarter results were mixed as it beat estimates for...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
Morningstar· 3 days ago(NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara ...
Bellwether Health Giant J&J Skids As Psoriasis Blockbuster Drags Top Line
Investor's Business Daily· 3 days agoJohnson & Johnson stock skidded early Tuesday after light sales of blockbuster psoriasis treatment ...
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara (NYSE:TEVA)
Seeking Alpha· 3 days agoThe FDA has approved Alvotech’s biosimilar of Johnson & Johnson’s (JNJ) Stelara, with Teva hoping to...
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Investor's Business Daily· 4 hours agoAbbott's EPS declined 5%, while J&J's rose 12%. Abbott beat sales forecasts, but issued light...
J&J's medical device sales fall short, cancer drugs seen growing
Reuters via Yahoo News· 3 days ago(Reuters) -Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical...
Analyst updates Johnson & Johnson stock price target after earnings
TheStreet via Yahoo Finance· 7 hours ago“While sequential growth was roughly flat due to phasing, we continue to anticipate...
The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and...
Zacks via Yahoo Finance· 11 hours agoPer the Zacks analyst, headwinds like generic competition and pricing pressure continue to ail. The...
Ads
related to: Stelara